480,642 Shares in AbbVie Inc. $ABBV Purchased by Life Cycle Investment Partners Ltd

Life Cycle Investment Partners Ltd bought a new position in shares of AbbVie Inc. (NYSE:ABBV) during the 4th quarter, Holdings Channel.com reports. The firm bought 480,642 shares of the company’s stock, valued at approximately $109,822,000.

Several other large investors have also recently added to or reduced their stakes in ABBV. Wellington Management Group LLP lifted its position in AbbVie by 457.4% during the third quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock worth $2,439,714,000 after buying an additional 8,646,424 shares during the period. Vanguard Group Inc. lifted its position in AbbVie by 1.7% during the fourth quarter. Vanguard Group Inc. now owns 180,779,699 shares of the company’s stock worth $41,306,353,000 after buying an additional 3,032,438 shares during the period. Raymond James Financial Inc. lifted its position in AbbVie by 41.8% during the second quarter. Raymond James Financial Inc. now owns 9,337,480 shares of the company’s stock worth $1,733,222,000 after buying an additional 2,753,312 shares during the period. Alliancebernstein L.P. lifted its position in AbbVie by 31.8% during the third quarter. Alliancebernstein L.P. now owns 7,281,327 shares of the company’s stock worth $1,685,918,000 after buying an additional 1,758,657 shares during the period. Finally, Amundi lifted its position in AbbVie by 15.6% during the third quarter. Amundi now owns 10,508,317 shares of the company’s stock worth $2,418,909,000 after buying an additional 1,414,621 shares during the period. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

AbbVie Price Performance

AbbVie stock opened at $216.02 on Friday. The stock’s 50-day moving average is $208.72 and its 200-day moving average is $219.68. The company has a market cap of $381.65 billion, a price-to-earnings ratio of 106.41, a price-to-earnings-growth ratio of 0.74 and a beta of 0.32. AbbVie Inc. has a 12 month low of $181.71 and a 12 month high of $244.81.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, topping analysts’ consensus estimates of $2.59 by $0.06. The company had revenue of $15 billion for the quarter, compared to the consensus estimate of $14.72 billion. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The company’s quarterly revenue was up 12.4% compared to the same quarter last year. During the same period last year, the business posted $2.46 EPS. Research analysts anticipate that AbbVie Inc. will post 14.3 EPS for the current year.

Insider Transactions at AbbVie

In other news, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the sale, the senior vice president owned 2,654 shares in the company, valued at approximately $619,868.24. This trade represents a 66.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the sale, the executive vice president owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. This trade represents a 36.98% decrease in their position. The SEC filing for this sale provides additional information. 0.06% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities analysts recently weighed in on ABBV shares. Bank of America upgraded AbbVie from a “neutral” rating to a “buy” rating and set a $234.00 target price on the stock in a research report on Thursday, April 30th. Wall Street Zen lowered AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 17th. Citigroup cut their price objective on AbbVie from $235.00 to $230.00 and set a “neutral” rating on the stock in a report on Tuesday, January 27th. Piper Sandler raised their price objective on AbbVie from $294.00 to $298.00 and gave the stock an “overweight” rating in a report on Thursday, May 14th. Finally, Canaccord Genuity Group raised their price objective on AbbVie from $262.00 to $265.00 and gave the stock a “buy” rating in a report on Thursday, April 30th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, AbbVie currently has an average rating of “Moderate Buy” and a consensus target price of $253.43.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie received a positive opinion from the European Medicines Agency’s CHMP for MAVIRET in acute hepatitis C, a potential label expansion that could broaden the drug’s commercial opportunity in Europe. Article Title
• Positive Sentiment: Allergan Aesthetics, an AbbVie company, also secured a positive CHMP opinion for Boey, adding another potential European growth catalyst for AbbVie’s aesthetics business. Article Title
• Positive Sentiment: AbbVie highlighted new oncology data at ASCO 2026, signaling continued momentum across its next-generation cancer pipeline and supporting longer-term growth expectations. Article Title
• Positive Sentiment: Analyst and media commentary remained constructive, with pieces calling AbbVie a strong dividend pick and a long-term buy, which can reinforce investor confidence in the stock. Article Title
• Neutral Sentiment: AbbVie plans 85 summer layoffs in California tied to its Allergan Aesthetics unit, a cost-cutting move that may draw attention but is not large enough on its own to materially change the investment case. Article Title

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.